Tetra Bio-Pharma Inc., a leader in cannabinoid-based drug discovery and development (TSX VENTURE: TBP) (OTCQB:TBPMF), is pleased to announce that Mr. Steeve Neron has joined Tetra Bio-Pharma as Vice-President, Marketing, effective August 20, 2018. He will be responsible for all Tetra Bio-Pharma and Tetra Natural Heath marketing activities.
Steeve has more than 32 years’ experience in the pharmaceutical industry with demonstrated success in numerous therapeutic sectors including cardiology, rheumatology, endocrinology, women’s health, asthma/COPD, OTC and dermatology where challenging the reimbursement landscape factored prominently in his role. Prior to joining Tetra Bio-Pharma he occupied a senior marketing position at Bausch Health Canada, formerly Valeant.
Steeve has held various marketing, sales, finance, material management and business development positions and has worked to launch or rejuvenate numerous market leading pharmaceutical brands including Aerius(TM) (antihistamine), Altace(TM) (hypertension), Ezetrol(TM) (cholesterol), Eliquis(TM) (anti-coagulant), Lodalis(TM) (cholesterol) and Contrave(TM) (Obesity).
“I am very proud to add Steeve to our senior management team. His vast experience will enable Tetra to achieve its high standards in executional excellence,” says Richard Giguere Executive Vice-President, Commercial Operations.
“I am very excited to have the opportunity of contributing my pharmaceutical marketing knowledge within the growing cannabinoid-based products sector,” said Steeve Neron. “Tetra has set the bar high from a clinical development standpoint and this is a critical factor to maximize the therapeutic potential of cannabis.”
About Tetra Bio-Pharma
Tetra Bio-Pharma (TSXV:TBP.VN) (OTCQB:TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and development with a Health Canada approved, and FDA reviewed, clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. The Company has several subsidiaries engaged in the development of an advanced and growing pipeline of Bio Pharmaceuticals, Natural Health and Veterinary Products containing cannabis and other medicinal plant-based elements. With patients at the core of what we do, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies.
For more information visit: www.tetrabiopharma.com
Source: Tetra Bio-Pharma
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company’s research and development strategies, including the ability to obtain orphan drug status, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. While no definitive documentation has yet been signed by the parties and there is no certainty that such documentation will be signed. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.
For further information, please contact Tetra Bio-Pharma Inc.
Robert (Bob) Bechard
Executive Vice President, Corporate Development and Licensing
514-288-8500 ext. 225
416-425-9143 ext. 225
<img src=”http://www.globenewswire.com/newsroom/ti?ndecode=MTUwIzczNzA2NTc=” alt=”” width=”1″ height=”1″/>